Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating two forms of buprenorphine treatment for Veterans with moderate to severe opioid use disorder OUD. The study compares a long-acting injectable buprenorphine given every 28 days with the standard daily sublingual buprenorphine. This open-label, randomized trial involves 952 Veterans over a 7-year recruitment period and follows them actively for 52 weeks, with additional passive follow-up for up to 10 years. The study also examines effects on substance use, overdose rates, infectious disease status, psychiatric symptoms, housing, dental health, and cost-effectiveness. Participants are first inducted on daily sublingual buprenorphine following SAMHSA guidelines. After reaching a target dose between 4 and 32 mg within 45 days, they are randomized 11 to either continue daily sublingual doses or receive a monthly injectable buprenorphine dose of 300 mg or 100 mg if needed. Study visits occur weekly for the first month, then every two weeks up to week 52, with medication management provided at each visit. Both treatments are administered under clinical supervision with dosing adjustments as needed. Throughout the study, participants complete self-reported opioid use and provide urine samples biweekly. Researchers collect data on retention in treatment, opioid abstinence, overdose events, infectious disease testing, healthcare utilization, craving, psychiatric symptoms, criminal justice involvement, and dental quality of life. After one year of active participation, administrative records are reviewed for ongoing outcomes for up to 10 years. This comprehensive monitoring aims to provide long-term insights into treatment effectiveness and patient well-being.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.
Actively Recruiting
Researchers are evaluating the combination of fruquintinib and FOLFIRI as a second-line treatment for adults with metastatic colorectal cancer mCRC. This open-label Phase II trial focuses on assessing the effectiveness and safety of this combination in participants previously treated with first-line therapies including oxaliplatin, fluoropyrimidine, and bevacizumab. The study excludes those with certain genetic mutations and aims to enroll up to 60 participants. Participants will receive fruquintinib orally for 21 days followed by a 7-day break in each 28-day cycle. Concurrently, they will receive FOLFIRI intravenously every 2 weeks within each cycle. Treatment continues until disease progression or unacceptable side effects. The FOLFIRI regimen includes irinotecan, leucovorin, and 5-fluorouracil, with possible adjustment to the 5-fluorouracil bolus based on prior treatment tolerance. During the study, participants will be closely monitored with assessments every two cycles 56 days including progression-free survival evaluation, response rates, duration of response, disease control, and overall survival. Safety is tracked through adverse event monitoring from consent to 30 days after treatment ends, up to one year. The total study duration for each participant may last up to two years to fully capture treatment outcomes and safety data.
Actively Recruiting
Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.
Actively Recruiting
Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy with or without the drug INCB161734 in people with metastatic pancreatic ductal adenocarcinoma PDAC that has a specific KRAS G12D mutation. This is a Phase 3 randomized, double-blind trial aiming to compare these treatments in patients who have not received prior systemic treatment for their metastatic cancer. Participants will receive either oral INCB161734 tablets or placebo tablets alongside chemotherapy chosen by the investigator, either mFOLFIRINOX or GemNabP, as per the study protocol. The study compares these two groups to assess outcomes such as survival and response to treatment. Treatment and observation will continue for up to approximately two to three years depending on the outcome being measured. During the trial, participants will undergo regular assessments including survival monitoring, tumor response evaluations by blinded independent central review and investigator assessments, and quality of life questionnaires. Researchers will also monitor adverse events and organ function. The study involves scheduled visits and tests over the course of treatment and follow-up lasting up to several years to understand long-term effects and treatment impact.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of ENERGI-F703 GEL in treating diabetic foot ulcers classified as Wagner Grade 1 to Grade 2. This Phase 3, randomized, double-blind, vehicle-controlled study includes participants with ulcers of different sizes and aims to compare the gel against a vehicle control across multiple centers. The total study duration is up to 31 weeks, encompassing screening, treatment, and safety follow-up phases. Participants will be randomly assigned to receive either ENERGI-F703 GEL or a matching vehicle gel, both applied topically twice daily for 16 weeks. The study uses a web-based system to assign participants to one of the two groups. After the treatment phase, a 12-week safety follow-up is conducted to monitor participants. Initial screening lasts approximately 2 to 3 weeks before treatment begins. Throughout the study, participants undergo regular assessments including evaluation of ulcer closure rates at week 16, and monitoring of ulcer healing progress at multiple time points. Safety is tracked by recording adverse events from week 1 through week 28. Participants will have visits to assess wound status, adverse events, and overall health, with the primary outcome being the complete closure of the ulcer by week 16.
Actively Recruiting
Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.
1-10 of 33
1